Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.55 |
| ▸ | MMP1 | P03956 | 15/20 | 0.55 |
| ▸ | MMP3 | P08254 | 9/20 | 0.55 |
| ▸ | MMP9 | P14780 | 9/20 | 0.55 |
| ▸ | MMP13 | P45452 | 7/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130071 | 1.00 | ADAM17 (0.55) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6239527 | 0.90 | ADAM17 (0.46) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL7138231 | 0.86 | MMP1 (0.65) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6241360 | 0.86 | MMP1 (0.65) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6237207 | 0.86 | MMP1 (0.65) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6427714 | 0.86 | MMP1 (0.65) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6239622 | 0.86 | MMP1 (0.65) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6234233 | 0.86 | ADAM17 (0.58) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6427715 | 0.86 | MMP1 (0.65) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6233856 | 0.86 | ADAM17 (0.43) | ADAM17MMP1MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1104412-B1 | TACE INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1104412-A1 | TACE INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | claimed |
| WO-2000009492-A1 | TACE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | claimed |
| EP-1104412-B1 | TACE INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1487457-A1 | COMBINATION OF AN IL-1/18 INHIBITOR WITH A TNF INHIBITOR FOR THE TREATMENT OF INFLAMMATION | Pfizer Products Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030143230-A1 | Combination of an IL-1/18 inhibitor with a TNF inhibitor for the treatment of inflammation | PFIZER INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003045400-A1 | COMBINATION OF AN IL-1/18 INHIBITOR WITH A TNF INHIBITOR FOR THE TREATMENT OF INFLAMMATION | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1104412-A1 | TACE INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009492-A1 | TACE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143230-A1 | Combination of an IL-1/18 inhibitor with a TNF inhibitor for the treatment of inflammation | IL1A, IL1B, IL18 | ADAM17 184/4885MMP1 61/4885MMP3 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.